Q2 EPS Estimates for Immunovant Lowered by Leerink Partnrs

Key Points

• Leerink Partners has decreased its Q2 2026 earnings per share (EPS) estimate for Immunovant from ($0.66) to ($0.71), with a full-year EPS estimate of ($2.69).
• The company's recent quarterly earnings showed an EPS of ($0.60), surpassing the consensus estimate of ($0.69) by $0.09.
• Immunovant's stock is currently trading at $15.32, showing a significant drop from its 12-month high of $34.47.

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Analysts at Leerink Partnrs reduced their Q2 2026 earnings estimates for shares of Immunovant in a research report issued to clients and investors on Monday, August 11th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.71) for the quarter, down from their prior estimate of ($0.66). The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. Leerink Partnrs also issued estimates for Immunovant's Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($3.06) EPS, FY2028 earnings at ($2.48) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at $0.85 EPS.

Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.09. During the same quarter in the prior year, the firm posted ($0.60) EPS.

Other equities research analysts have also recently issued research reports about the stock. The Goldman Sachs Group upgraded shares of Immunovant to a "hold" rating and set a $18.00 target price on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. decreased their target price on shares of Immunovant from $40.00 to $37.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Citigroup reiterated a "buy" rating on shares of Immunovant in a research report on Monday, August 11th. UBS Group lifted their price objective on shares of Immunovant from $17.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. Finally, Bank of America reduced their price objective on shares of Immunovant from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $35.20.

Immunovant Price Performance

NASDAQ IMVT traded up $0.02 on Thursday, reaching $15.22. 1,781,359 shares of the stock were exchanged, compared to its average volume of 1,321,870. Immunovant has a one year low of $12.72 and a one year high of $34.47. The company's 50-day simple moving average is $16.50 and its two-hundred day simple moving average is $16.90.

Insiders Place Their Bets

In related news, CTO Jay S. Stout sold 2,805 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total transaction of $50,910.75. Following the sale, the chief technology officer owned 204,919 shares of the company's stock, valued at $3,719,279.85. This represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Michael Geffner sold 2,385 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total transaction of $43,287.75. Following the sale, the insider directly owned 221,825 shares in the company, valued at approximately $4,026,123.75. The trade was a 1.06% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,869 shares of company stock worth $140,384. 1.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunovant

A number of hedge funds have recently bought and sold shares of IMVT. Alliancebernstein L.P. raised its stake in Immunovant by 5.9% during the fourth quarter. Alliancebernstein L.P. now owns 74,850 shares of the company's stock valued at $1,854,000 after purchasing an additional 4,200 shares in the last quarter. Geode Capital Management LLC increased its position in Immunovant by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 1,515,020 shares of the company's stock valued at $37,536,000 after acquiring an additional 4,094 shares during the last quarter. Wells Fargo & Company MN increased its position in Immunovant by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 28,063 shares of the company's stock valued at $695,000 after acquiring an additional 9,349 shares during the last quarter. Raymond James Financial Inc. bought a new position in Immunovant during the fourth quarter valued at $505,000. Finally, XTX Topco Ltd bought a new position in Immunovant during the fourth quarter valued at $563,000. Hedge funds and other institutional investors own 47.08% of the company's stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.